Rett gene regulates alternative splicing

October 17, 2005

HOUSTON (Oct. 17, 2005) - The gene responsible for Rett syndrome, a devastating neurological disease found mostly in girls, not only silences some genes but in combination with another also regulates alternative splicing, crucial to the formation of proteins -- a finding that may explain the symptoms associated with this puzzling disorder and others related to it, said Baylor College of Medicine researchers in a report appearing online today in the Proceedings of the National Academy of Sciences.

The finding brings a new understanding to the ongoing process of unraveling the mystery behind why neurons work and do not work.

"There are multiple steps that a neuron goes through as it makes a decision to communicate with another neuron," said senior author Dr. Huda Y. Zoghbi, professor of pediatrics and human and molecular genetics at BCM as well as a Howard Hughes Medical Institute investigator. "The neuron will express certain genes producing RNA, make certain proteins from these RNAs, and then carry some of these proteins to synapse. Alternative RNA splicing is one way for the cell to create many different forms of RNA and proteins from the same gene. We are just beginning to learn the importance of alternative splicing in neuronal activity." Zoghbi discovered the role of the gene methyl-CpG binding protein 2 (MeCP2) in Rett.

"In fact, the effect of this protein (MeCP2) on RNA splicing is more noticeable than its effect on gene expression," she said. Rett syndrome occurs in approximately 1 in 10,000 girls. As infants, those who have the disorder seem normal at birth and at least six months after. Between the ages of 6 and 18 months, however, their development stops and they begin to regress, losing the ability to talk. Then they begin to have problems walking and keeping their balance and develop typical hand-wringing behavior. Often they develop a curvature of the spine, difficulty in interacting with other people and mood disorders, among other problems. At some point, the regression stops but they do not acquire new abilities.

Scientists know that mutations in MECP2 are associated with these symptoms in Rett as well as other disorders such as autism and a variety of X-linked mental retardation syndromes as well.

Understanding how one gene could result in all these problems led Zoghbi and her team to take a new look at MeCP2, which was known to repress the expression of some genes. In studies involving cells and mice, they found that a protein called Y box-binding protein 1 or YB-1 binds to MeCP2 consistently. YB-1 protein is involved in regulation of alternative splicing, a process by which one gene can provide the code for many different proteins.

Genes are organized into portions that code for proteins (called exons) and intervening sequences (called introns). Normally a cell pastes together the exons to generate the RNA that will be translated to a protein. In alternative splicing, the cell uses various combinations of exons to generate diverse sets of RNA and proteins. That is the reason that fewer than 30,000 human genes are predicted to make more than 100,000 proteins.

Loss of MeCp2 function can cause dramatic changes in alternative splicing, said Zoghbi. In fact, these changes are more evident in a mouse model of Rett syndrome than than the expected gene expression changes given the known role of MeCP2 in regulating gene expression.

"When a gene level is increased or decreased by 20 to 40 percent, as has been found for some of the gene targets of this protein, you expect consequences," she said. "When the gene makes a different protein, however, you can expect more severe consequences in the neuron."
Others who participated in this research include: Juan I. Young, Eugene P. Hong, John Castle, Aaron B. Bowman, Matthew F. Rose, Dongcheul Kang, Ron Richman and Susan Berget, all of BCM, and Juan Crespo-Barreto and Jason Johnson of Rosetta Inpharmatics, LLC, Merck & Co. Funding for this work came form the Howard Hughes Medical Institute, Rett Syndrome Research Foundation, the National Institutes of Health, the Hereditary Disease Foundation and Cure Autism Now.

Baylor College of Medicine

Related Rett Syndrome Articles from Brightsurf:

Proteins -- and labs -- coming together to prevent Rett syndrome
Two labs investigated whether the disruption of one protein's condensate-forming ability contributes to Rett syndrome.

Genetic editing milestone in mouse model of Rett Syndrome
A genomic error that causes Rett Syndrome, a serious lifelong neurological disorder, can be corrected in the brains of mice by rewriting the genetic instructions carried by the RNA.

Yale researchers find potential treatment for Rett Syndrome
An experimental cancer drug can extend the life of mice with Rett Syndrome, a devastating genetic disorder that afflicts about one of every 10,000 to 15,000 girls within 6 to 18 months after birth, Yale researchers report June 10 in the journal Molecular Cell.

Research team investigates abnormal neuron activity in Rett syndrome
Research by Billy Lau, a postdoctoral researcher working with Assistant Professor Keerthi Krishnan at the University of Tennessee, Knoxville, examines the time during which an adult female mouse first learns to recognize and respond to the distress cries of young mouse pups as an opportunity for the brain to rewire and learn again.

A dietary supplement improves skills of an atypical Rett syndrome patient
Administration of the amino acid L-serine, a dietary supplement, contributes to the improvement of the communicative and motor skills of a patient with a mutation that alters glutamate receptors.

A new drug shows preclinical efficacy in Rett syndrome
A new article published in the Cell Reports describes how a new drug is able to reduce the symptoms and activate the dormant neurons characteristic of Rett Syndrome in preclinical models.

X chromosome reactivation could treat Rett syndrome, other X-linked disorders
A study from a team of Massachusetts General Hospital investigators points toward a potential strategy for treating X-linked disorders -- those caused by mutations in the X chromosome -- in females.

Discovery fuels hope for Rett syndrome treatment
Vanderbilt University researchers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.

Drug improves brain performance in Rett syndrome mice
A brain penetrant drug -- a small-molecule mimetic of BDNF, or brain derived neurotrophic factor -- is able to improve brain performance in Rett syndrome mice -- specifically synaptic plasticity in the hippocampus and object location memory.

Small-molecule therapeutic boosts spatial memory and motor function in Rett syndrome mice
Rett syndrome is a neurological disorder affecting learning and development, caused by a mutation in the MECP2 gene triggering decreased levels of brain-derived neurotrophic factor (BDNF).

Read More: Rett Syndrome News and Rett Syndrome Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to